< 1.0 EU per μg of the protein as determined by the LAL method
1.Measured by its binding ability in a functional ELISA. 2.Immobilized human TNFRSF9 (Cat:10041-H08H) at 10μg/mL (100μL/well) can bind human TNFSF9 (Cat:15693-H01H),the EC50 of human TNFSF9 is 7-40ng/mL.
A DNA sequence encoding the human 4-1BB extracellular domain (NP_001552.2) (Met 1-Gln 186) was fused with a polyhistidine tag at the C-terminus.
The recombinant human 4-1BB consists of 174 amino acids and has a calculated molecular mass of 18.8 kDa. By SDS-PAGE under reducing conditions, the apparent molecular mass of rh4-1BB is approximately 33-36 kDa due to glycosylation.
Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. 2. Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
稳定性 & 储存条件
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃ Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
CD137 Protein, Human, Recombinant (His Tag): 图片
CD137 Protein, Human, Recombinant (His Tag): 别称
4-1BB Protein, Human; CD137 Protein, Human; CDw137 Protein, Human; ILA Protein, Human
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.
Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.